

1 ROB BONTA
Attorney General of California
2 JAMES M. LEDAKIS
Supervising Deputy Attorney General
3 ARMANDO ZAMBRANO
Supervising Deputy Attorney General
4 WILLIAM D. GARDNER
Deputy Attorney General
5 State Bar No. 244817
300 So. Spring Street, Suite 1702
6 Los Angeles, CA 90013
Telephone: (213) 269-6292
7 Facsimile: (916) 731-2126
Attorneys for Complainant
8

9
10 **BEFORE THE**
BOARD OF PHARMACY
11 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA
12

13 In the Matter of the Statement of Issues
14 Against:

Case No. 7127

15 **MOAZZEM HOSSAIN CHOWDHURY**
16 **DBA CROWN VALLEY PHARMACY**

STATEMENT OF ISSUES

17 **Pharmacy License Applicant**

18 Respondent.
19

20 **PARTIES**

21 1. Anne Sodergren (Complainant) brings this Statement of Issues solely in her official
22 capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

23 2. On or about September 10, 2020, the Board of Pharmacy, Department of Consumer
24 Affairs received an application for a Pharmacy License from Moazzem Hossain Chowdhury
25 (Respondent) dba Crown Pharmacy. On or about August 1, 2020, Respondent certified under
26 penalty of perjury to the truthfulness of all statements, answers, and representations in the
27 application. The Board denied the application on February 10, 2021.

28 ///

1 **Respondent's License History**

2 3. On or about September 16, 1993, the Board of Pharmacy issued Pharmacist License
3 Number RPH 46737 to Respondent. Pursuant to the decision and order in the disciplinary action
4 entitled *In the Matter of the Accusation Against Moazzem H. Chowdhury, dba Desert Drugs, et*
5 *al*, Case No. 3917 (OAH No. 2014010146), effective October 22, 2014, the Pharmacist License
6 was placed on probation for a period of four (4) years. Respondent's Pharmacist License will
7 expire on February 28, 2023, unless renewed.

8 **JURISDICTION**

9 4. This Statement of Issues is brought before the Board under the authority of the
10 following laws. All section references are to the Business and Professions Code ("Code") unless
11 otherwise indicated.

12 **STATUTORY PROVISIONS**

13 5. Section 4300, subdivision (c), of the Code provides, in pertinent part, that the Board
14 "may refuse a license to any applicant guilty of unprofessional conduct."

15 6. Section 4301 of the Code states, in pertinent part:

16 "The board shall take action against any holder of a license who is guilty of unprofessional
17 conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but
18 is not limited to, any of the following:

19 . . .

20 "(j) The violation of any of the statutes of this state, or any other state, or of the United
21 States regulating controlled substances and dangerous drugs.

22 . . .

23 "(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the
24 violation of or conspiring to violate any provision or term of this chapter or of the applicable
25 federal and state laws and regulations governing pharmacy, including regulations established by
26 the board or by any other state or federal regulatory agency."

27 ///

28 ///

1 7. Section 4302 of the Code states:

2 “The board may deny, suspend, or revoke any license where conditions exist in relation to
3 any person holding 10 percent or more of the ownership interest or where conditions exist in
4 relation to any officer, director, or other person with management or control of the license that
5 would constitute grounds for disciplinary action against a licensee.”

6 8. Section 4307 of the Code states:

7 (a) Any person who has been denied a license or whose license has been revoked or is
8 under suspension, or who has failed to renew his or her license while it was under suspension, or
9 who has been a manager, administrator, owner, member, officer, director, associate, partner, or
10 any other person with management or control of any partnership, corporation, trust, firm, or
11 association whose application for a license has been denied or revoked, is under suspension or has
12 been placed on probation, and while acting as the manager, administrator, owner, member,
13 officer, director, associate, partner, or any other person with management or control had
14 knowledge of or knowingly participated in any conduct for which the license was denied,
15 revoked, suspended, or placed on probation, shall be prohibited from serving as a manager,
16 administrator, owner, member, officer, director, associate, partner, or in any other position with
17 management or control of a licensee as follows:

18 (1) Where a probationary license is issued or where an existing license is placed on
19 probation, this prohibition shall remain in effect for a period not to exceed five years.

20 (2) Where the license is denied or revoked, the prohibition shall continue until the license is
21 issued or reinstated.

22 (b) “Manager, administrator, owner, member, officer, director, associate, partner, or any
23 other person with management or control of a license” as used in this section and Section 4308,
24 may refer to a pharmacist or to any other person who serves in such capacity in or for a licensee.

25 (c) The provisions of subdivision (a) may be alleged in any pleading filed pursuant to
26 Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of the Government Code.
27 However, no order may be issued in that case except as to a person who is named in the caption,
28 as to whom the pleading alleges the applicability of this section, and where the person has been

1 given notice of the proceeding as required by Chapter 5 (commencing with Section 11500) of Part
2 1 of Division 3 of the Government Code. The authority to proceed as provided by this subdivision
3 shall be in addition to the board's authority to proceed under Section 4339 or any other provision
4 of law.

5 **Pertinent State Regulatory Law**

6 9. Section 4081 of the Code states:

7 "(a) All records of manufacture and of sale, acquisition, or disposition of dangerous drugs
8 or dangerous devices shall be at all times during business hours open to inspection by authorized
9 officers of the law, and shall be preserved for at least three years from the date of making. A
10 current inventory shall be kept by every manufacturer, wholesaler, pharmacy, veterinary
11 food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital,
12 institution, or establishment holding a currently valid and unrevoked certificate, license, permit,
13 registration, or exemption under Division 2 (commencing with Section 1200) of the Health and
14 Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and
15 Institutions Code who maintains a stock of dangerous drugs or dangerous devices.

16 "(b) The owner, officer, and partner of any pharmacy, wholesaler, or veterinary food-animal
17 drug retailer shall be jointly responsible, with the pharmacist-in-charge or representative-in-
18 charge, for maintaining the records and inventory described in this section.

19 10. Section 4105 of the Code states, in pertinent part:

20 "(a) All records or other documentation of the acquisition and disposition of dangerous
21 drugs and dangerous devices by any entity licensed by the board shall be retained on the licensed
22 premises in a readily retrievable form.

23 . . .

24 "(c) The records required by this section shall be retained on the licensed premises for a
25 period of three years from the date of making.

26

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

11. Health and Safety Code section 11165, subdivision (d), provides:

“For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven days after the date a controlled substance is dispensed, in a format specified by the Department of Justice:

- (1) Full name, address, and, if available, telephone number of the ultimate user or research subject, or contact information as determined by the Secretary of the United States Department of Health and Human Services, and the gender, and date of birth of the ultimate user.
- (2) The prescriber's category of licensure, license number, national provider identifier (NPI) number, if applicable, the federal controlled substance registration number, and the state medical license number of any prescriber using the federal controlled substance registration number of a government-exempt facility.
- (3) Pharmacy prescription number, license number, NPI number, and federal controlled substance registration number.
- (4) National Drug Code (NDC) number of the controlled substance dispensed.
- (5) Quantity of the controlled substance dispensed.
- (6) International Statistical Classification of Diseases, 9th revision (ICD-9) or 10th revision (ICD-10) Code, if available.
- (7) Number of refills ordered.
- (8) Whether the drug was dispensed as a refill of a prescription or as a first-time request.
- (9) Date of origin of the prescription.
- (10) Date of dispensing of the prescription.”

///

1 12. Health and Safety Code section 11205 provides:

2 “The owner of a pharmacy or any person who purchases a controlled substance upon
3 federal order forms as required pursuant to the provisions of the Federal “Comprehensive Drug
4 Abuse Prevention and Control Act of 1970,” (P.L. 91-513, 84 Stat. 1236),¹ relating to the
5 importation, exportation, manufacture, production, compounding, distribution, dispensing, and
6 control of controlled substances, and who sells controlled substances obtained upon such federal
7 order forms in response to prescriptions shall maintain and file such prescriptions in a separate
8 file apart from noncontrolled substances prescriptions. Such files shall be preserved for a period
9 of three years.”

10 13. Health and Safety Code section 11208 provides:

11 “In a prosecution under this division, proof that a defendant received or has had in his
12 possession at any time a greater amount of controlled substances than is accounted for by any
13 record required by law or that the amount of controlled substances possessed by the defendant is a
14 lesser amount than is accounted for by any record required by law is prima facie evidence of
15 guilt.”

16 14. Health and Safety Code section 11209, subdivision (a), provides in pertinent part:

17 “No person shall deliver Schedule II, III, or IV controlled substances to a pharmacy or
18 pharmacy receiving area, nor shall any person receive controlled substances on behalf of a
19 pharmacy unless, at the time of delivery, a pharmacist or authorized receiving personnel signs a
20 receipt showing the type and quantity of the controlled substances received.”

21 15. California Code of Regulations, title 16, section 1714, states in pertinent part:

22 “(b) Each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and
23 equipment so that drugs are safely and properly prepared, maintained, secured and distributed.
24 The pharmacy shall be of sufficient size and unobstructed area to accommodate the safe practice
25 of pharmacy.

26 . . .

27 (d) Each pharmacist while on duty shall be responsible for the security of the prescription
28 department, including provisions for effective control against theft or diversion of dangerous

1 drugs and devices, and records for such drugs and devices. Possession of a key to the pharmacy
2 where dangerous drugs and controlled substances are stored shall be restricted to a pharmacist.

3 . . .

4 **Pertinent Federal Regulatory Law**

5 16. Federal Code of Regulations, title 21, section 1304.04, subdivision (h), provides in
6 pertinent part:

7 “Each registered pharmacy shall maintain the inventories and records of controlled
8 substances as follows:

- 9 (1) Inventories and records of all controlled substances listed in Schedule I and II
10 shall be maintained separately from all other records of the pharmacy.

11 . . .

12 17. Federal Code of Regulations, title 21, section 1304.11, provides:

13 “(a) General requirements. Each inventory shall contain a complete and accurate record of
14 all controlled substances on hand on the date the inventory is taken, and shall be maintained in
15 written, typewritten, or printed form at the registered location. An inventory taken by use of an
16 oral recording device must be promptly transcribed. Controlled substances shall be deemed to be
17 “on hand” if they are in the possession of or under the control of the registrant, including
18 substances returned by a customer, ordered by a customer but not yet invoiced, stored in a
19 warehouse on behalf of the registrant, and substances in the possession of employees of the
20 registrant and intended for distribution as complimentary samples. A separate inventory shall be
21 made for each registered location and each independent activity registered, except as provided in
22 paragraph (e)(4) of this section. In the event controlled substances in the possession or under the
23 control of the registrant are stored at a location for which he/she is not registered, the substances
24 shall be included in the inventory of the registered location to which they are subject to control or
25 to which the person possessing the substance is responsible. The inventory may be taken either as
26 of opening of business or as of the close of business on the inventory date and it shall be indicated
27 on the inventory.

28 ///

1 Among other things, the complaint alleged that Respondent, Crown Valley’s manager, was
2 selling oxycodone pills and a codeine-laced cough syrup (i.e., promethazine with codeine) to
3 people without a prescription. Oxycodone and promethazine with codeine are commonly abused
4 controlled substances with significant street values.

5 20. Oxycodone is a Schedule II controlled substance pursuant to Health and Safety Code
6 section 11055, subdivision (b)(1)(M) and is a dangerous drug pursuant to Code section 4022.

7 21. Promethazine with codeine is a Schedule V controlled substance pursuant to Health
8 and Safety Code section 11058, subdivision (c) and is a dangerous drug pursuant to Code section
9 4022.

10 22. On or about August 13, 2015, a Board inspector performed an inspection of Crown
11 Valley Pharmacy. Federal law requires pharmacies to complete and maintain an “initial
12 inventory” of any and all controlled substances in its stock as of the first day on which the
13 pharmacy begins dispensing controlled substances and also requires that subsequent “biennial
14 inventories” be performed at least every two (2) years thereafter. (See 21 CFR § 1304.) Among
15 other things, the inspector asked to review Crown Valley’s initial controlled substance inventory.
16 Although Crown Valley had been in operation and dispensed controlled substances prior to
17 January 30, 2014, the initial controlled substance inventory was not performed and/or completed
18 until January 30, 2014. In addition, the inventory for Schedule II controlled substances was not
19 maintained separately from all other records of the pharmacy as required by federal law.
20 The inspector advised Respondent, as Crown Valley Pharmacy’s manager, that a complete and
21 compliant inventory should be performed and provided to the Board. The Board received a copy
22 of the newly completed controlled substance inventory the following day.

23 23. The inspector also obtained a variety of records related to Crown Valley Pharmacy’s
24 acquisition and dispensing of: (1) oxycodone; (2) oxycodone with acetaminophen (hereinafter,
25 “oxycodone/apap”); and (3) promethazine with codeine between September 2013 and August
26 2015. Those documents included acquisition records from pharmaceutical wholesalers used by
27 Crown Valley Pharmacy, the pharmacy’s own dispensing records, records related to the
28

1 pharmacy's transactions with a reverse distributor, original prescriptions, and reports from the
2 Controlled Substance Utilization Review and Evaluation System ("CURES.")¹

3 24. These records revealed a vast disparity between the pharmacy's actual inventory of
4 certain controlled substances and the legally documented inventory that should have been present.
5 Specifically, the records demonstrated that Crown Valley was short in its inventory of oxycodone
6 30 mg by 3,666 pills, short in its inventory of oxycodone 10 mg by 326 pills, and short in its
7 inventory of promethazine with codeine by 63 bottles (i.e. approximately 30,000 ml). Moreover,
8 the records revealed that Crown Valley Pharmacy also could not account for the presence of
9 massive amounts of other controlled substances in its inventory. For example, Crown Valley's
10 inventory included 5,196 oxycodone/apap 5-325 mg pills for which there were no acquisition
11 records, 22,579 oxycodone/apap 10-325 mg pills for which there were no acquisition records,
12 1,233 oxycodone 5 mg pills for which there were no acquisition records, 433 oxycodone/apap
13 7.5-325 mg pills for which there were no acquisition records, 148 oxycodone 20 mg pills for
14 which there were no acquisition records, and 34 oxycodone 15 mg pills for which there were no
15 acquisition records.

16 25. The inspector's analysis of the records also revealed multiple discrepancies between
17 the quantities of oxycodone and oxycodone/apap dispensed pursuant to actual prescriptions
18 versus the quantity dispensed pursuant to the pharmacy's dispensing records and the number of
19 prescriptions and quantity dispensed as reported to CURES. In addition, Crown Valley Pharmacy
20 could not produce the original prescriptions for six (6) purported prescriptions of oxycodone and
21 oxycodone/apap that it had filled and fifteen (15) purported prescriptions of promethazine with
22 codeine, indicating that the pharmacy had dispensed the drugs without prescriptions. The
23 inspector also obtained a variety of records related to Crown Valley Pharmacy's acquisition and
24 dispensing of: (1) oxycodone; (2) oxycodone with acetaminophen (hereinafter,

25 ¹¹ CURES is a system for monitoring patient controlled substance history information.
26 California Health and Safety Code section 11165 requires pharmacies to report within 7 days to
27 the California Department of Justice every schedule II, III and IV drug prescription that is written
28 or dispensed, and the information provided establishes the CURES database, which includes
information about the drug dispensed, drug quantity and strength, patient name, address,
prescriber name, and prescriber authorization number including DEA number and prescription
number.

1 “oxycodone/apap”); and (3) promethazine with codeine between September 2013 and August
2 2015. Those documents included acquisition records from pharmaceutical wholesalers used by
3 Crown Valley Pharmacy, the pharmacy’s own dispensing records, records related to the
4 pharmacy’s transactions with a reverse distributor, original prescriptions, and reports from
5 CURES.

6 26. These records revealed a vast disparity between the pharmacy’s actual inventory of
7 certain controlled substances and the legally documented inventory that should have been present.
8 Specifically, the records demonstrated that Crown Valley was short in its inventory of oxycodone
9 30 mg by 3,666 pills, short in its inventory of oxycodone 10 mg by 326 pills, and short in its
10 inventory of promethazine with codeine by 63 bottles (i.e. approximately 30,000 ml). Moreover,
11 the records revealed that Crown Valley Pharmacy also could not account for the presence of
12 massive amounts of other controlled substances in its inventory. For example, Crown Valley’s
13 inventory included 5,196 oxycodone/apap 5-325 mg pills for which there were no acquisition
14 records, 22,579 oxycodone/apap 10-325 mg pills for which there were no acquisition records,
15 1,233 oxycodone 5 mg pills for which there were no acquisition records, 433 oxycodone/apap
16 7.5-325 mg pills for which there were no acquisition records, 148 oxycodone 20 mg pills for
17 which there were no acquisition records, and 34 oxycodone 15 mg pills for which there were no
18 acquisition records.

19 27. The inspector’s analysis of the records also revealed multiple discrepancies between
20 the quantities of oxycodone and oxycodone/apap dispensed pursuant to actual prescriptions
21 versus the quantity dispensed pursuant to the pharmacy’s dispensing records and the number of
22 prescriptions and quantity dispensed as reported to CURES.

23 **FIRST CAUSE FOR DENIAL OF APPLICATION**

24 **(Prohibited Pursuant to B&P Section 4307)**

25 28. Respondent's application is subject to denial under Code section 4307 in that while
26 serving as the manager of Crown Valley Pharmacy and/or as someone exercising control over the
27 pharmacy, Respondent had knowledge of or knowingly participated in conduct for which Crown
28 Valley Pharmacy’s license was placed on probation. Complainant refers to, and by this reference

1 incorporates, the allegations set forth above in paragraphs 18 through 27, inclusive, as though set
2 forth fully herein.

3 **SECOND CAUSE FOR DENIAL**

4 **(Unprofessional Conduct)**

5 29. Respondent's application is subject to denial under Code section 4300, subdivision
6 (c), and Code section 4302, in that Respondent engaged in unprofessional conduct while serving
7 as the manager of Crown Valley Pharmacy and/or as someone exercising control over the
8 pharmacy. Complainant refers to, and by this reference incorporates, the allegations set forth
9 above in paragraphs 18 through 27, inclusive, as though set forth fully herein.

10 **THIRD CAUSE FOR DENIAL**

11 **(Violation of Pharmacy Law: Acquisition & Disposition Records)**

12 30. Respondent's application is subject to denial under Code sections 4300, subdivision
13 (c), and 4302, in conjunction with Code sections 4301, subdivision (o), and 4105 in that, while
14 serving the manager of Crown Valley Pharmacy and/or as someone exercising control over the
15 pharmacy, Crown Valley Pharmacy failed to maintain acquisition, sale and/or disposition records
16 related to thousands of oxycodone and oxycodone/apap pills as well as dozens of bottles of
17 promethazine with codeine. Complainant refers to, and by this reference incorporates, the
18 allegations set forth above in paragraphs 18 through 27, inclusive, as though set forth fully herein.

19 **FOURTH CAUSE FOR DENIAL**

20 **(Violation of Pharmacy Law: Operational Standards)**

21 31. Respondent's application is subject to denial under Code sections 4300, subdivision
22 (c), and 4302, in conjunction with Code section 4301, subdivision (o), and California Code of
23 Regulations, title 16, section 1714, in that, while serving as the manager of Crown Valley
24 Pharmacy and/or as someone exercising control over the pharmacy, Crown Valley Pharmacy's
25 facilities, space, fixtures, and equipment were not maintained such that the pharmacy's drugs
26 were safely and properly maintained, secured and distributed as evidenced by the vast
27 discrepancies between its in-stock inventory and the inventory denoted by its acquisition and

28 ///

1 dispensing records. Complainant refers to, and by this reference incorporates, the allegations set
2 forth above in paragraphs 18 through 27, inclusive, as though set forth fully herein.

3 **FIFTH CAUSE FOR DENIAL**

4 **(Violation of Drug Law: Failure to Report to CURES)**

5 32. Respondent's application is subject to denial under Code sections 4300, subdivision
6 (c), and 4302, in conjunction with section 4301, subdivision (j), and California Health and Safety
7 Code section 11165, in that , while serving as the manager of Crown Valley Pharmacy and/or as
8 someone exercising control over the pharmacy, Crown Valley Pharmacy failed to report
9 information to the Department of Justice regarding Crown Valley Pharmacy's dispensing of
10 Schedule II controlled substances as required by state and federal law. Complainant refers to, and
11 by this reference incorporates, the allegations set forth above in paragraphs 18 through 27,
12 inclusive, as though set forth fully herein.

13 **SIXTH CAUSE FOR DENIAL**

14 **(Violation of Drug Law: Controlled Substance Inventories)**

15 33. Respondent's application is subject to denial under Code sections 4300, subdivision
16 (c), and 4302, in conjunction with section 4301, subdivision (j), and Code of Federal Regulations,
17 title 21, section 1304.11, in that, while serving as the manager of Crown Valley Pharmacy and/or
18 as someone exercising control over the pharmacy, Crown Valley Pharmacy failed to maintain
19 separate inventory records for its Schedule II controlled substances as required under federal law.
20 Complainant refers to, and by this reference incorporates, the allegations set forth above in
21 paragraphs 18 through 27, inclusive, as though set forth fully herein.

22 **SEVENTH CAUSE FOR DENIAL**

23 **(Violation Drug Law: Controlled Substance Prescriptions)**

24 34. Respondent's application is subject to denial under Code sections 4300, subdivision
25 (c), and 4302, in conjunction with section 4301, subdivision (j), in conjunction with Health and
26 Safety Code section 11205 in that, while serving as the manager of Crown Valley Pharmacy
27 and/or as someone exercising control over the pharmacy, Crown Valley Pharmacy failed to
28 maintain the original prescriptions for six (6) purported prescriptions of oxycodone and

1 oxycodone/apap and fifteen (15) purported prescriptions of promethazine with codeine that it
2 filled. Complainant refers to, and by this reference incorporates, the allegations set forth above in
3 paragraphs 18 through 27, inclusive, as though set forth fully herein.

4 **PRAYER**

5 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
6 and that following the hearing, the Board of Pharmacy issue a decision:

- 7 1. Denying the application of Moazzem Hossain Chowdhury dba Crown Pharmacy for a
8 Pharmacy License;
9 2. Taking such other and further action as deemed necessary and proper.

10
11 DATED: 7/1/2021

Signature on File

12 ANNE SODERGREN
13 Executive Officer
14 Board of Pharmacy
15 Department of Consumer Affairs
16 State of California
17 *Complainant*

18
19
20
21
22
23
24
25
26
27
28
LA2021601284
64217788.docx